Talmon Marco, CEO of H2Pro, believes his company’s technology can “significantly accelerate the solution or the move towards zero emissions”
Read more here.
Talmon Marco, CEO of H2Pro, believes his company’s technology can “significantly accelerate the solution or the move towards zero emissions”
Read more here.
![[Alpha Tau in PR Newswire] Alpha Tau announces results of first US clinical trial of Alpha DaRT™ in malignant skin & soft tissue cancers, showing complete response in all ten treated tumors at approximately 12 weeks and no product-related serious adverse events](https://blog.ourcrowd.net/wp-content/themes/Extra/images/post-format-thumb-text.svg)
